Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥10.2b (down 2.8% from 2Q 2023).
- Net income: CN¥615.1m (down 22% from 2Q 2023).
- Profit margin: 6.0% (down from 7.5% in 2Q 2023).
- EPS: CN¥0.23 (down from CN¥0.29 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Fosun Pharmaceutical (Group) Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 18%.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company’s shares are down 1.8% from a week ago.
Risk Analysis
We don’t want to rain on the parade…
